INTRODUCING WOCKAIR®

(budesonide/formoterol fumarate dihydrate, inhalation powder)

Choose WockAIR® 160/4.5mcg as your preferred controller and reliever for your patients with asthma aged 12 years and over at all treatment steps1.

  • ICS/formoterol inhaler licensed in adults and adolescents over 12 years in the UK for AIR-only and MART1
  • Budesonide/formoterol reduces the risk of asthma exacerbations compared to SABA containing regimens1-5
  • ICS/formoterol anti-inflammatory reliever is recommended by GINA and it replaces SABA5
  • Your patients will only need one inhaler1,5
  • WockAIR® has a 32% lower NHS list price than Symbicort9
  • Bioequivalent to the originator Symbicort Turbohaler

    (based on 80-125% bioequivalence limits for AUC, Cmax, and standard flow parameters) 6

  • Patient friendly device with a lower carbon footprint than pMDIs7,8
Learn more
WockAir
WockAIR Icon

ASTHMA

WockAIR® is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate:¹

WockAIR information

WockAIR®160/4.5mcg is also indicated as reliever therapy for adults and adolescents (12 years and older) with mild asthma

COPD

WockAIR® is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with COPD with forced expiratory volume in 1 second (FEV1) <70% predicted normal (post bronchodilator) and an exacerbation history despite regular bronchodilator therapy¹

Adverse events should be reported. Reporting forms and information can be found at: https://yellowcard.mhra.gov.uk/

Adverse events should also be reported to Wockhardt UK. Please contact us or email us at drug.safety@wockhardt.co.uk

References

1. WockAIR® Summary of Product Characteristics
2. Sobieraj DM, Weeda ER, Nguyen E, et al. Association of inhaled corticosteroids and long-acting β-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma: a systematic review and meta-analysis. JAMA 2018; 319: 1485–1496
3. Beasley R, DSc; Harrison T, Peterson S et al. Evaluation of Budesonide-Formoterol for Maintenance and Reliever Therapy Among Patients With Poorly Controlled Asthma: A Systematic Review and Meta-analysis. JAMA Network Open. 2022;5(3):e220615. doi:10.1001/jamanetworkopen.2022.0615
4. Crossingham I et al. Cochrane Database Syst Rev 2021; 5(5): CD013518
5. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2023. Updated July 2023. Available from www.ginasthma.org

 

6. Wockhardt Data on File
7. Janson C, et al. Thorax 2020;75:82–84. doi:10.1136/thoraxjnl-2019-213744. Carbon footprint impact of the choice of inhalers for asthma and COPD
8. Virchow JC, Weuthen T, Harmer QJ, Jones S. Identifying the features of an easy-to-use and intuitive dry powder inhaler for asthma and chronic obstructive pulmonary disease therapy: results from a 28-day device handling study, and an airflow resistance study. Expert Opin Drug Deliv. 2014;11(12):1849–57
9. MIMS April 2023

This site is intended for UK Healthcare Professionals.
Contact Us | Cookies and Privacy Policy | Terms of and Conditions of Use | Sitemap | PIL | Pharmacovigilance Privacy Notice
Job code: AIR01/21 August 2021